Longitudinal Development of Cardiorespiratory Fitness Parameters in Youth Athletes: A Multiyear Analysis of Peak Aerobic Power and Peak Exercise Performance
International Journal of Sports Physiology and Performance · 01.06.2026 · 21 (6) · 748-757
DOI: 10.1123/ijspp.2025-0465 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Sports Physiology and Performance, erschienen am 01.06.2026. Verfasst von Katharina Köble und 6 weiteren Autor:innen. Beteiligte Einrichtung: Chair of Preventive Pediatrics, School of Medicine and Health,Technical University Munich, München, Germany. Hauptthemen laut MEDLINE: Cardiorespiratory Fitness, Athletic Performance. Die Arbeit nennt 102 Literaturangaben.
Abstract (Originalsprache)
Purpose
While the development of cardiorespiratory fitness in normally active children and adolescents is well-documented, longitudinal data on physiological adaptations to training in youth athletes remain limited. This study aimed to investigate the long-term development of cardiorespiratory fitness in young competitive athletes over a period of 2–6 years.
Methods
A total of 397 young athletes (48 girls), aged 8–20 years, from a variety of sports underwent up to 6 repeated assessments between 2012 and 2024. Peak exercise performance ( W max ) and peak aerobic power (VO 2 peak), both were measured via cardiopulmonary exercise testing on an electronically braked cycle ergometer. A linear mixed model analysis was used to evaluate longitudinal changes in VO 2 peak and W max (both normalized to body mass), including body surface area and training intensity (MET-hours/week) as fixed effects, with sex-stratified analyses.
Results
A total of 1009 cardiopulmonary exercise testing were analyzed. At baseline, boys showed higher age-specific VO 2 peak and W max , while girls had higher age-specific VO 2 peak despite similar training intensity. Longitudinally, VO 2 peak increased significantly with age in mid-adolescent girls and boys, particularly in endurance athletes, and was positively associated with training intensity. W max rose with age but was less influenced by training or sport type, showing a stronger relationship with growth-related factors like body surface area.
Conclusions
VO 2 peak development in youth athletes is influenced by age, body size, training intensity, and sport type, making it a sensitive marker of aerobic adaptation. In contrast, W max reflects primarily maturational growth and is less responsive to training-specific factors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Chair of Preventive Pediatrics, School of Medicine and Health,Technical University Munich, München, Germany.
ORCID-Profile: Katharina Köble, Laura Willinger, Tobias Engl, Stefanie Huber, Maximilian Dettenhofer, Renate Oberhoffer
Zitieren
APA
Köble, K., Willinger, L., Engl, T., Mühlbauer, F., Huber, S., Dettenhofer, M., & Oberhoffer, R. (2026). Longitudinal Development of Cardiorespiratory Fitness Parameters in Youth Athletes: A Multiyear Analysis of Peak Aerobic Power and Peak Exercise Performance. International Journal of Sports Physiology and Performance, 21(6), 748-757. https://doi.org/10.1123/ijspp.2025-0465
Vancouver
Köble K, Willinger L, Engl T, Mühlbauer F, Huber S, Dettenhofer M, et al. Longitudinal Development of Cardiorespiratory Fitness Parameters in Youth Athletes: A Multiyear Analysis of Peak Aerobic Power and Peak Exercise Performance. International Journal of Sports Physiology and Performance. 2026;21(6):748-757. doi:10.1123/ijspp.2025-0465
BibTeX
@article{Kble2026,
author = {Köble, Katharina and Willinger, Laura and Engl, Tobias and Mühlbauer, Frauke and Huber, Stefanie and Dettenhofer, Maximilian and Oberhoffer, Renate},
title = {Longitudinal Development of Cardiorespiratory Fitness Parameters in Youth Athletes: A Multiyear Analysis of Peak Aerobic Power and Peak Exercise Performance},
journal = {International Journal of Sports Physiology and Performance},
year = {2026},
volume = {21},
number = {6},
pages = {748--757},
doi = {10.1123/ijspp.2025-0465}
}
EUVIMED